Recent Research Analysts’ Ratings Updates for Novartis (NVS)
by Doug Wharley · The Cerbat GemA number of research firms have changed their ratings and price targets for Novartis (NYSE: NVS):
- 12/22/2025 – Novartis had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 12/15/2025 – Novartis had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 12/10/2025 – Novartis had its “reduce” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $112.00 price target on the stock.
- 12/8/2025 – Novartis had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 12/8/2025 – Novartis was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating.
- 12/3/2025 – Novartis had its “overweight” rating reaffirmed by analysts at Morgan Stanley.
- 12/2/2025 – Novartis had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 11/28/2025 – Novartis was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
- 11/26/2025 – Novartis had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 11/25/2025 – Novartis was upgraded by analysts at Bank of America Corporation from a “neutral” rating to a “buy” rating.
- 11/20/2025 – Novartis had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 11/10/2025 – Novartis had its “hold” rating reaffirmed by analysts at Cowen Inc.
- 11/1/2025 – Novartis was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating.
- 10/31/2025 – Novartis was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating.
- 10/31/2025 – Novartis had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
- 10/29/2025 – Novartis was given a new $126.00 price target on by analysts at Cfra. They now have a “hold” rating on the stock.
- 10/29/2025 – Novartis was upgraded by analysts at Cfra Research to a “hold” rating.
- 10/27/2025 – Novartis was downgraded by analysts at HC Wainwright to a “neutral” rating.
- 10/27/2025 – Novartis had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc..
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.
The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.